中国医疗保险
中國醫療保險
중국의료보험
CHINA HEALTH INSURANCE
2015年
7期
21-23,29
,共4页
药品价格%政府定价%医保支付标准
藥品價格%政府定價%醫保支付標準
약품개격%정부정개%의보지부표준
drug price%the government pricing%health insurance payment standard
本文在总结上世纪90年代以来药品价格政策变化和得失的基础上，对医保支付标准形成机制进行展望，提出医保支付标准应与集中招标采购和加成管制政策的改革同步推进、应调动各主体参与市场活动的积极性、对于缺乏竞争品的创新药可引入价值评估结果和谈判机制、政府和医保部门应主动收集和披露药品价格信息、加强对医生处方的监管等建议。
本文在總結上世紀90年代以來藥品價格政策變化和得失的基礎上，對醫保支付標準形成機製進行展望，提齣醫保支付標準應與集中招標採購和加成管製政策的改革同步推進、應調動各主體參與市場活動的積極性、對于缺乏競爭品的創新藥可引入價值評估結果和談判機製、政府和醫保部門應主動收集和披露藥品價格信息、加彊對醫生處方的鑑管等建議。
본문재총결상세기90년대이래약품개격정책변화화득실적기출상，대의보지부표준형성궤제진행전망，제출의보지부표준응여집중초표채구화가성관제정책적개혁동보추진、응조동각주체삼여시장활동적적겁성、대우결핍경쟁품적창신약가인입개치평고결과화담판궤제、정부화의보부문응주동수집화피로약품개격신식、가강대의생처방적감관등건의。
Based on summarizing the changes, gain and loss of drug price policy since 1990s, and looking forward on medical insurance payment standard system, certain suggestions have been put forward, that is, the standard of insurance payment should be simultaneously propelled with the reform of centralized bid procurement and bonus control policies, and, the enthusiasm of different subjects to participate in marketing activities should be mobilized. For the innovation drugs lacking of competition, doctors’ prescriptions should be intensively monitored based on the price evaluation results and negotiation mechanism, and by drug prices information collected and announced by governments and health insurance departments.
